Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma-Lyte 148 versus saline for diabetic ketoacidosis
ACTRN12618001622291Phase 2Completed
- Sponsor
- Trial Management Committee
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in diabetic ketoacidosis (DKA) comparing Sites starting with Plasma-Lyte 148 with Sites starting with 0.9% sodium chloride (2 arms). Primary endpoint: Change in base excess on arterial blood gas. Started Sep 2019; status: completed.
02
Drugs
plasma-lytesodium chloride
03
Conditions
diabetic ketoacidosis (DKA)
Beyond the preview
Go deeper on ACTRN12618001622291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001622291.